Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 35 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Apostolidis, Apostolos [Clear All Filters]
(2021).
Can we improve our diagnosis of impaired detrusor contractility in women? An ICI-RS 2019 proposal..
Neurourol Urodyn. 39 Suppl 3, S43-S49.
(2020). Healthcare Access, Quality, and Satisfaction Among Albanian Immigrants Using the Emergency Department in Northern Greece..
J Immigr Minor Health. 22(3), 512-525.
(2020). Intravesical Botox for Overactive Bladder: How to Minimize Complications and Manage Failures.
Current Drug Targets. 21(15), 1527 - 1536.
(2020). Intravesical Botox for overactive bladder; how to minimize complications and manage failures..
Curr Drug Targets.
(2020). Neurourological Management After Failed Intradetrusor OnabotulinumtoxinA Injections..
Eur Urol Focus. 6(5), 814-816.
(2020). Should we routinely assess psychological morbidities in idiopathic lower urinary tract dysfunction: ICI-RS 2019?.
Neurourol Urodyn. 39 Suppl 3, S70-S79.
(2020). Are psychological comorbidities important in the aetiology of lower urinary tract dysfunction-ICI-RS 2018?.
Neurourol Urodyn. 38 Suppl 5, S8-S17.
(2019). Can we improve our management of dysfunctional voiding in children and adults: International Consultation on Incontinence Research Society; ICI-RS2018?.
Neurourol Urodyn. 38 Suppl 5, S82-S89.
(2019). Stem cells and lower urinary tract dysfunction: Has its potential finally reached clinical maturity? ICI-RS2018..
Neurourol Urodyn. 38 Suppl 5, S134-S141.
(2019).
(2019). 6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: EVALUATION AND TREATMENT OF URINARY INCONTINENCE, PELVIC ORGAN PROLAPSE AND FAECAL INCONTINENCE..
Neurourol Urodyn. 37(7), 2271-2272.
(2018). Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study..
Int J Urol. 25(8), 737-745.
(2018). The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol..
Neurourol Urodyn. 37(S4), S99-S107.
(2018). Neurogenic bowel dysfunction: Clinical management recommendations of the Neurologic Incontinence Committee of the Fifth International Consultation on Incontinence 2013..
Neurourol Urodyn. 37(1), 46-53.
(2018). Subtle errors of bladder wall thickness measurement have a significant impact on the calculation of ultrasound-estimated bladder weight. A pilot study..
Med Ultrason. 20(3), 292-297.
(2018). Is there "brain OAB" and how can we recognize it? International Consultation on Incontinence-Research Society (ICI-RS) 2017..
Neurourol Urodyn. 37(S4), S38-S45.
(2018). Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)..
Neurourol Urodyn. 36(4), 882-893.
(2017). Combination treatments for overactive bladder refractory to first-line pharmacotherapy: do they meet expectations?.
BJU Int. 120(4), 459-460.
(2017). How does lower urinary tract dysfunction affect sexual function in men and women? ICI-RS 2015-Part 1..
Neurourol Urodyn. 36(4), 949-952.
(2017). How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2..
Neurourol Urodyn. 36(4), 869-875.
(2017). Neurogenic voiding dysfunction..
Curr Opin Urol. 27(3), 300-306.
(2017). The urinary microbiome and its contribution to lower urinary tract symptoms; ICI-RS 2015..
Neurourol Urodyn. 36(4), 850-853.
(2017). Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014..
Neurourol Urodyn. 35(2), 293-8.
(2016).
(2016).